🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "major milestone" in the fight against superbug strains of the bacteria, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are escalating worldwide, with estimates suggesting over 82 million new cases per year. Particularly high rates are seen in Africa and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. In England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely development in the context of rising global incidence, escalating drug resistance and the very limited available drugs presently on offer.”

Medical experts are particularly alarmed about the surge in treatment-resistant strains. The World Health Organization has classified it as a "high-priority threat". Recent surveillance showed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Gain Approval

One new antibiotic, alternatively called a brand name, was authorized by the American regulatory agency in recent days for use against gonorrhoea. This infection can lead to major issues, including infertility. Researchers anticipate that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, was also approved in concurrent days. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment emerged from a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to see it through.

“This approval marks a huge turning point in the therapy of highly resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Clinical Trial Results and Worldwide Availability

Based on results published in a prominent scientific publication, the new drug successfully treated more than 90% of cases of the STI. This establishes an comparable level with the current standard treatment, which involves an injection and a pill. The study enrolled over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the authority to license and sell the drug in numerous regions with limited resources.

Medical professionals treating patients have shared hope. Having a single-dose, oral treatment like this is described as a "critical tool" for gonorrhoea control. This is considered crucial to reduce the burden of the illness for people and to stop the proliferation of extremely resistant gonorrhoea around the world.